文献速递骨质疏松与钙磷/甲状旁腺

布罗索单抗与传统治疗对X连锁低磷血症年幼与年长儿童疗效比较

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该事后分析基于一项64周开放标签随机对照研究,纳入61例1至12岁X连锁低磷血症(XLH)患儿,比较布罗索单抗与磷酸盐制剂联合活性维生素D(Pi/D)的疗效与安全性。结果显示布罗索单抗在年幼(<5岁)和年长(5-12岁)患儿中均较Pi/D改善佝偻病、下肢畸形、生长和碱性磷酸酶(ALP)等结局。

要点

  • 布罗索单抗较Pi/D改善年幼和年长XLH患儿的RGI-C佝偻病总分(LSMD分别为+0.90和+1.07)。
  • 布罗索单抗组年长患儿53%报告牙脓肿,年幼患儿未报告。
  • 布罗索单抗在年幼和年长患儿中均改善下肢畸形、生长和ALP等结局。

核心结论

  • 与Pi/D相比,布罗索单抗似乎改善年幼和年长XLH患儿的结局,包括佝偻病、下肢畸形、生长和ALP。

研究设计与样本

  • 一项64周、开放标签、随机对照研究的事后分析,在16个学术中心开展。
  • 共纳入61例1至12岁XLH患儿,年幼(<5岁)26例,年长(5-12岁)35例。
  • 布罗索单抗组从0.8 mg/kg每2周开始(年幼14例,年长15例),Pi/D组按推荐指南个体化滴定继续治疗(年幼12例,年长20例)。

主要发现

  • 从基线至第64周,布罗索单抗 vs Pi/D的RGI-C佝偻病总分LSMD:年幼+0.90,年长+1.07。
  • 总佝偻病严重度评分LSMD:年幼-0.86,年长-1.44。
  • RGI-C下肢畸形评分LSMD:年幼+1.02,年长+0.91。
  • 仰卧身长或站立身高Z评分LSMD:年幼+0.20,年长+0.09。
  • 血清ALP(占正常上限[ULN]百分比)LSMD:年幼-31.15%,年长-52.11%;布罗索单抗组牙脓肿在年幼患儿中未报告,年长患儿中53%报告。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Younger age at treatment onset with conventional therapy (phosphate salts and active vitamin D; Pi/D) is associated with improved growth and skeletal outcomes in children with X-linked hypophosphatemia (XLH). The effect of age on burosumab efficacy and safety in XLH is unknown. OBJECTIVE: This work aimed to explore the efficacy and safety of burosumab vs Pi/D in younger (< 5 years) and older (5-12 years) children with XLH. METHODS: This post hoc analysis of a 64-week, open-label, randomized controlled study took place at 16 academic centers. Sixty-one children aged 1 to 12 years with XLH (younger, n = 26; older, n = 35) participated. Children received burosumab starting at 0.8 mg/kg every 2 weeks (younger, n = 14; older, n = 15) or continued Pi/D individually titrated per recommended guidelines (younger, n = 12; older, n = 20). The main outcome measure included the least squares means difference (LSMD) in Radiographic Global Impression of Change (RGI-C) rickets total score from baseline to week 64. RESULTS: The LSMD in outcomes through 64 weeks on burosumab vs conventional therapy by age group were as follows: RGI-C rickets total score (younger, +0.90; older, +1.07), total Rickets Severity Score (younger, -0.86; older, -1.44), RGI-C lower limb deformity score (younger, +1.02; older, +0.91), recumbent length or standing height Z-score (younger, +0.20; older, +0.09), and serum alkaline phosphatase (ALP) (younger, -31.15% of upper normal limit [ULN]; older, -52.11% of ULN). On burosumab, dental abscesses were not reported in younger children but were in 53% of older children. CONCLUSION: Burosumab appears to improve outcomes both in younger and older children with XLH, including rickets, lower limb deformities, growth, and ALP, compared with Pi/D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ward LM, Glorieux FH, Whyte MP, et al. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. J Clin Endocrinol Metab. 2022. PMID: 35533340. doi:10.1210/clinem/dgac296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。